Direct Answer
Fertility service providers run clinics that offer in vitro fertilization, egg freezing and genetic testing, mostly paid by patients out of pocket or through employer benefits. Volumes depend on age patterns, coverage and cost per cycle.
Industry Overview
Fertility Services sits within the health care sector. The first numbers to compare across companies here are cycles performed, revenue per cycle and employer-covered share. The outside forces that move them are listed under Primary Macro Drivers.
Key Industry Metrics
- Cycles performed: Number of treatment cycles, such as IVF egg retrievals, completed by clinics. It is the basic volume measure, and growth can come from more patients, more clinics or more cycles per patient.
- Revenue per cycle: Average payment collected per treatment cycle including medications, testing and add-ons. Rising figures can reflect price increases or added services, but patient affordability limits how far this can go.
- Employer-covered share: Portion of cycles paid for through employer benefits instead of patients' own money. Coverage widens access and steadies demand, so a rising share points to less price sensitivity.
- Clinic openings and utilization: New clinics and how fully existing capacity is used. New sites take time to reach volume, so strong utilization at mature clinics matters more than openings alone.
- Success rate disclosures: Published rates of live births or pregnancies per cycle. Patients weigh these when choosing clinics, but they depend on patient age and case mix, so compare only like groups.
Primary Macro Drivers
- Delayed parenthood and age at first birth: Later age at first birth increases demand for treatment and egg freezing, so it supports cycles performed over time.
- Employer fertility benefits: When employers cover fertility care, more patients can afford cycles, so benefit adoption raises volume and the employer-covered share.
- State insurance mandates: States that require coverage expand access for plan members, which lifts cycles in those states and revenue per cycle for providers.
- Consumer financing options: Financing spreads the high out-of-pocket cost over time, which lets more patients start treatment and supports cycle volume.
Major Risks
- Regulatory and legal changes on embryo handling: Court decisions and laws on embryos can change how clinics operate or add cost and liability; watch legal disclosures and state-level developments.
- Consumer discretionary pressure: Patients paying out of pocket may postpone treatment when budgets are tight, which lowers cycles performed; watch volume trends and clinic utilization.
- Malpractice and mix-up exposure: Errors in handling embryos or eggs can lead to lawsuits and reputational damage; watch legal proceedings and insurance cost.
- Talent and lab quality: Success depends on lab and clinician skill, so losing key staff or quality lapses can reduce outcomes and referrals; watch success rate disclosures.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Mixed |
| Capital Intensity | Medium |
| Regulatory Intensity | Medium |
| Industry Maturity | Growth |
| Geographic Importance | U.S. / Global |
Companies Associated with Fertility Services
The SEC's Standard Industrial Classification has no code that describes fertility services as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.
| Company | SEC classification | Revenue | Growth | Net margin | Year |
|---|---|---|---|---|---|
| Cooper Companies, Inc. | Ophthalmic Goods | $4.1 billion | 5.1% | 9.2% | FY 2025 |
| Natera, Inc. | Services-Medical Laboratories | $2.3 billion | 35.9% | -9.0% | FY 2025 |
Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the company directory and the health care hub.
Where to Go Next
The Fertility Services guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Gene Editing
- European Pharmaceuticals
- Gene Therapy
- Electronic Health Records
- Generic Pharmaceuticals
- Drug Discovery Platforms
- Genomics & Sequencing
- Digital Therapeutics
Put it to work
Frequently Asked Questions
What are the main KPIs for the Fertility Services industry?
Key performance indicators for the Fertility Services industry include: Cycles performed, Revenue per cycle, Employer-covered share, Clinic openings and utilization, Success rate disclosures. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Fertility Services industry?
The Fertility Services industry exhibits mixed cyclicality characteristics. Some segments move with the broader economy while others maintain more stable demand, making stock selection within the group particularly important.
What are the biggest risks in the Fertility Services industry?
The primary risks for Fertility Services companies include: Regulatory and legal changes on embryo handling, Consumer discretionary pressure, Malpractice and mix-up exposure, Talent and lab quality. Investors should assess each company's exposure to these factors and its track record of navigating them.